TPCW
CRL icon

TD Private Client Wealth’s Charles River Laboratories CRL Stock Holding History

TD Private Client Wealth’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5K Hold
113
– – ﹤0.01% 1015
2025
Q4 		$22.5K Hold
113
– – ﹤0.01% 995
2025
Q3 		$17.7K Sell
113
-108
-49% -$17.2K ﹤0.01% 996
2025
Q2 		$33.5K Sell
221
-8,311
-97% -$1.11M ﹤0.01% 905
2025
Q1 		$1.28M Sell
8,532
-490
-5% -$82.2K 0.04% 296
2024
Q4 		$1.67M Sell
9,022
-320
-3% -$61.6K 0.05% 259
2024
Q3 		$1.84M Sell
9,342
-2,883
-24% -$599K 0.05% 257
2024
Q2 		$2.53M Sell
12,225
-24
-0.2% -$5.44K 0.08% 191
2024
Q1 		$3.32M Buy
12,249
+2,612
+27% +$624K 0.11% 149
2023
Q4 		$2.28M Sell
9,637
-263
-3% -$51.7K 0.08% 194
2023
Q3 		$1.94M Sell
9,900
-744
-7% -$153K 0.08% 209
2023
Q2 		$2.24M Sell
10,644
-55
-0.5% -$10.9K 0.1% 205
2023
Q1 		$2.16M Sell
10,699
-342
-3% -$77.5K 0.1% 209
2022
Q4 		$2.41M Sell
11,041
-1,559
-12% -$340K 0.11% 186
2022
Q3 		$2.48M Sell
12,600
-300
-2% -$64.8K 0.13% 167
2022
Q2 		$2.76M Sell
12,900
-714
-5% -$174K 0.13% 163
2022
Q1 		$3.87M Buy
13,614
+1,389
+11% +$428K 0.16% 136
2021
Q4 		$4.61M Sell
12,225
-635
-5% -$247K 0.19% 117
2021
Q3 		$5.31M Buy
12,860
+6
+0% +$2.49K 0.23% 96
2021
Q2 		$4.75M Sell
12,854
-6,844
-35% -$2.29M 0.2% 108
2021
Q1 		$5.71M Sell
19,698
-119
-0.6% -$33.1K 0.27% 86
2020
Q4 		$4.95M Buy
19,817
+624
+3% +$149K 0.25% 91
2020
Q3 		$4.35M Sell
19,193
-290
-1% -$60.2K 0.24% 90
2020
Q2 		$3.4M Buy
19,483
+1,768
+10% +$282K 0.2% 112
2020
Q1 		$2.24M Sell
17,715
-978
-5% -$147K 0.16% 133
2019
Q4 		$2.86M Buy
+18,693
New +$2.59M 0.17% 141

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TD Private Client Wealth's CRL Position: Q1 2026 in Review

TD Private Client Wealth held its Charles River Laboratories (CRL) position steady in Q1 2026 at 113 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

TD Private Client Wealth first reported a position in CRL in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.71M in Q1 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • TD Private Client Wealth held 113 shares of Charles River Laboratories worth $19.5K as of Q1 2026.
  • TD Private Client Wealth left its Charles River Laboratories share count unchanged in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #1015 holding.
  • TD Private Client Wealth first reported a position in Charles River Laboratories in Q4 2019 and has held it in 26 quarters since.
  • TD Private Client Wealth's Charles River Laboratories position peaked at $5.71M in Q1 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.